Associated Papers
Using Patient Feedback to Improve Treatment Outcomes for Patients with Congenital Dyserythropoietic Anaemia Type I Receiving Interferon Therapy.
Frey K et al.
Journal of Clinical Medicine, 2026
MMS22L is a novel key actor of normal and pathological erythropoiesis.
Colin E et al.
Hemasphere, 2025
Severe Neonatal Anemia with Multi-Organ Failure, Extreme Placentomegaly, and Placental Megaloblastic Erythroblastosis as Features in Identifying Congenital Dyserythropoietic Anemia Type 1: A Case Report.
Roose O et al.
Neonatology, 2025
Unveiling the genetic landscape of suspected congenital dyserythropoietic anemia type I: A retrospective cohort study of 36 patients.
Marra R et al.
American Journal of Hematology, 2024
Genetic and functional insights into CDA-I prevalence and pathogenesis.
Olijnik AA et al.
Journal of Medical Genetics, 2021
Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR).
Niss O et al.
Blood Cells, Molecules & Diseases, 2021
The pathogenesis, diagnosis and management of congenital dyserythropoietic anaemia type I.
Roy NBA et al.
British Journal of Haematology, 2019
Clinical and genetic features of congenital dyserythropoietic anemia (CDA).
Moreno-Carralero MI et al.
European Journal of Haematology, 2018
Select a paper to view details